Depression is one of the most common mental health issues, affecting over 320 million people globally. Research shows that exercise may be an effective treatment option for many battling this disabling condition. Key Facts: Exercise has comparable antidepressant effects to medications and psychotherapy in clinical trials. Both aerobic and resistance training reduce depressive symptoms, with …
Researchers conducted a comprehensive analysis comparing 20 antidepressants to identify the most effective options for preventing relapse in patients with major depressive disorder (MDD). Their findings suggest desvenlafaxine, paroxetine, venlafaxine and vortioxetine balance efficacy and tolerability best for maintenance treatment. Key Facts: The analysis included 34 high-quality clinical trials with over 9,300 patients total. All …
Major depressive disorder (MDD) is a global health crisis affecting over 300 million people. While available antidepressants help some patients, treatment is far from satisfactory for many. Exciting research into rapid-acting agents like ketamine and psilocybin combined with exploration of novel drug targets finally offers real hope for transformational change in how depression is treated. …
New research finds that regular running is just as effective as antidepressants for treating depression and anxiety, and leads to better physical health outcomes. Key Facts: In a study of 141 patients, running therapy and antidepressant medication had comparable effects on rates of remission (no longer meeting diagnostic criteria) from depression/anxiety disorders. However, running led …
Depression affects over 300 million people globally. Current antidepressants have limited efficacy and slow onset of action. New research shows promise for compounds targeting metabotropic glutamate receptors 2 and 3 (mGluR2/3) as fast-acting antidepressants with fewer side effects. Key Facts: 1/3 of depressed patients are treatment-resistant with current antidepressants mGluR2/3 inhibitors show robust, rapid (within …
New research reveals that increased inflammation, indicated by higher levels of a protein called VCAM-1, is associated with decreased gray matter and altered brain connectivity in patients with major depressive disorder (MDD). These brain changes also correlate with VCAM-1 levels. Key Facts: MDD patients had higher blood VCAM-1 levels than healthy controls Higher VCAM-1 related …
A new study examined whether metabolic biomarkers assessed through a high-throughput method are associated with future depressive symptoms. The results suggest the metabolites may not play a direct role in depression development. Key Facts: Researchers investigated associations between 121 metabolic measures and depressive symptoms at 7-year follow-up. Some metabolites showed tendencies for links with more …
A new meta-analysis found that continuous theta burst stimulation (cTBS), a novel form of brain stimulation therapy, does not appear to be more effective than sham (placebo) stimulation for treating symptoms of major depression. Key Facts: cTBS is a type of repetitive transcranial magnetic brain stimulation that aims to modulate activity in certain brain regions …
Eating foods rich in certain flavonoids may help lower the risk of experiencing depressive symptoms, suggests new research based on U.S. national health data. Key facts: Higher intakes of anthocyanidins, flavanones, flavones, and isoflavones were associated with lower odds of depressive symptoms after adjusting for confounders. There was an inverse association between total flavonoid intake …
An innovative study aims to assess the feasibility of patients self-managing transcranial direct current stimulation (tDCS) therapy for depression at home. This digitally-supported model could greatly expand access if proven safe, reliable and effective. Key Facts: tDCS uses scalp electrodes to deliver targeted electrical currents modulating brain activity Applied to prefrontal cortex, tDCS can have …
